Moderna, Recordati to Develop and Commercialize Metabolic Disorder Drug

Dow Jones01-30

By Katherine Hamilton

Moderna agreed to work with Recordati in a deal worth up to $160 million to advance development of a drug designed to treat the metabolic disorder propionic acidemia.

The partnership with the Italian pharmaceutical company will help mRNA-3927 move through the final stages of clinical development and, pending approval, global commercialization, Moderna said.

Under the terms of the deal, Moderna will get an upfront payment of $50 million, plus up to $110 million in near-term development and regulatory milestones. It will also receive commercial and sales milestones and tiered royalties on net sales.

The Cambridge, Mass., biopharma giant will continue to lead the clinical development of the drug through approval, and then Recordati will lead commercialization.

The transaction is subject to closing conditions, including U.S. antitrust clearance, which is expected within 30 days from the relevant filing.

mRNA-3927 is currently being evaluated in a registrational study that has reached target enrollment. Moderna expects a potential data readout this year.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

January 29, 2026 17:43 ET (22:43 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2607052201?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-30 06:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2607052201","market":"sh","top_or_hot":-1,"title":"Moderna, Recordati to Develop and Commercialize Metabolic Disorder Drug","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/MRNA\">Moderna</a> agreed to work with Recordati in a deal worth up to $160 million to advance development of a drug designed to treat the metabolic disorder propionic acidemia. \n</p>\n<p>\n  The partnership with the Italian pharmaceutical company will help mRNA-3927 move through the final stages of clinical development and, pending approval, global commercialization, Moderna said. \n</p>\n<p>\n  Under the terms of the deal, Moderna will get an upfront payment of $50 million, plus up to $110 million in near-term development and regulatory milestones. It will also receive commercial and sales milestones and tiered royalties on net sales. \n</p>\n<p>\n  The Cambridge, Mass., biopharma giant will continue to lead the clinical development of the drug through approval, and then Recordati will lead commercialization. \n</p>\n<p>\n  The transaction is subject to closing conditions, including U.S. antitrust clearance, which is expected within 30 days from the relevant filing. \n</p>\n<p>\n  mRNA-3927 is currently being evaluated in a registrational study that has reached target enrollment. Moderna expects a potential data readout this year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 29, 2026 17:43 ET (22:43 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna, Recordati to Develop and Commercialize Metabolic Disorder Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna, Recordati to Develop and Commercialize Metabolic Disorder Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-30 06:43</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/MRNA\">Moderna</a> agreed to work with Recordati in a deal worth up to $160 million to advance development of a drug designed to treat the metabolic disorder propionic acidemia. \n</p>\n<p>\n  The partnership with the Italian pharmaceutical company will help mRNA-3927 move through the final stages of clinical development and, pending approval, global commercialization, Moderna said. \n</p>\n<p>\n  Under the terms of the deal, Moderna will get an upfront payment of $50 million, plus up to $110 million in near-term development and regulatory milestones. It will also receive commercial and sales milestones and tiered royalties on net sales. \n</p>\n<p>\n  The Cambridge, Mass., biopharma giant will continue to lead the clinical development of the drug through approval, and then Recordati will lead commercialization. \n</p>\n<p>\n  The transaction is subject to closing conditions, including U.S. antitrust clearance, which is expected within 30 days from the relevant filing. \n</p>\n<p>\n  mRNA-3927 is currently being evaluated in a registrational study that has reached target enrollment. Moderna expects a potential data readout this year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 29, 2026 17:43 ET (22:43 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4548","symbol_name":"巴美列捷福持仓","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2607052201","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2607052201","pubTimestamp":1769726580,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Moderna agreed to work with Recordati in a deal worth up to $160 million to advance development of a drug designed to treat the metabolic disorder propionic acidemia.The partnership with the Italian pharmaceutical company will help mRNA-3927 move through the final stages of clinical development and, pending approval, global commercialization, Moderna said.Under the terms of the deal, Moderna will get an upfront payment of $50 million, plus up to $110 million in near-term development and regulatory milestones. It will also receive commercial and sales milestones and tiered royalties on net sales.The Cambridge, Mass., biopharma giant will continue to lead the clinical development of the drug through approval, and then Recordati will lead commercialization.The transaction is subject to closing conditions, including U.S. antitrust clearance, which is expected within 30 days from the relevant filing.mRNA-3927 is currently being evaluated in a registrational study that has reached target enr","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4548":"巴美列捷福持仓","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4532":"文艺复兴科技持仓","BK4568":"美国抗疫概念","MRNA":"Moderna, Inc.","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4501":"段永平概念","BK4551":"寇图资本持仓","BK4588":"碎股","BK4534":"瑞士信贷持仓"},"translate_title":"Moderna与Recordati将开发和商业化代谢紊乱药物","themeId":"b1d10af39e3603a6f0c840ebceb83a8d","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":0.9},"content_text":"By Katherine Hamilton \n\n\n \n\n\nModerna agreed to work with Recordati in a deal worth up to $160 million to advance development of a drug designed to treat the metabolic disorder propionic acidemia. \n\n\n  The partnership with the Italian pharmaceutical company will help mRNA-3927 move through the final stages of clinical development and, pending approval, global commercialization, Moderna said. \n\n\n  Under the terms of the deal, Moderna will get an upfront payment of $50 million, plus up to $110 million in near-term development and regulatory milestones. It will also receive commercial and sales milestones and tiered royalties on net sales. \n\n\n  The Cambridge, Mass., biopharma giant will continue to lead the clinical development of the drug through approval, and then Recordati will lead commercialization. \n\n\n  The transaction is subject to closing conditions, including U.S. antitrust clearance, which is expected within 30 days from the relevant filing. \n\n\n  mRNA-3927 is currently being evaluated in a registrational study that has reached target enrollment. Moderna expects a potential data readout this year. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 29, 2026 17:43 ET (22:43 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2607052201","isCrawlerRequest":true}